VVOS - Vivos spikes 41% on FDA clearance for sleep disorder therapy

• MedTech company Vivos Therapeutics ( NASDAQ: VVOS ) added ~41% pre-market Wednesday after announcing that the FDA issued 510(k) clearance for the company’s sleep disorder treatment, DNA appliance (daytime-nighttime appliance).
• With the latest clearance, the FDA recognizes the DNA appliance as a Class II device introducing a new treatment option (when combined with The Vivos Method) for mild-to-moderate obstructive sleep apnea.
• The Vivos Method is the company’s nonsurgical, cost-effective, nonpharmaceutical regimen to treat mild to moderate OSA.
• The device is designed to address the main cause of snoring and/or OSA in many by opening the airway and converting patients to nasal breathing from oral breathing.
• For several years, Vivos ( VVOS ) has marketed the DNA appliance for orthodontic treatments, such as jaw expansion and teeth positioning in adults and children.
• As of Q3 2022, the company treated more than 31K patients with The Vivos Method last year.

For further details see: